title: Nerve growth factor (NGF) restores depletions of calcitonin gene-related peptide and substance P in sensory neurons from diabetic mice in vitro.
abstract: Dorsal root ganglion neurons from streptozotocin (STZ)-induced diabetic, genetic diabetic and normal mice were cultured in serum-containing media with or without nerve growth factor (NGF). The immunocytochemical analysis carried out after 1 week in culture revealed that the ratios of neurons immunoreactive to calcitonin gene-related peptide (CGRP) in NGF-free medium in the STZ-diabetic mice (average 23.2%) were significantly lower than those in the normal mice (45.1%). The ratios of neurons immunoreactive to CGRP and substance P (SP) in the NGF-free medium were also lower in the genetic diabetic mice (23.6% and 21.8%) than those in the normal ones (40.7% and 34.2%). However, treatment with NGF restored these reduced immunoreactivities in the diabetic groups in a dose-dependent manner. These results show that NGF can be effective for the diabetes-induced depletion of CGRP and SP in sensory neurons, and suggest its possible role in the prevention and improvement of diabetic sensory neuropathy.
authors.affiliation: Department of Physiology, School of Medicine, Yokohama City University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sango
authors.forename: J M
authors.initials: JM
authors.lastname: Verdes
authors.forename: N
authors.initials: N
authors.lastname: Hikawa
authors.forename: H
authors.initials: H
authors.lastname: Horie
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Inoue
authors.forename: J R
authors.initials: JR
authors.lastname: Sotelo
authors.forename: T
authors.initials: T
authors.lastname: Takenaka
mesh_terms: D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000172:deficiency / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000150:complications* / Q000235:genetics; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000473:pathology; D003929:Diabetic Neuropathies / Q000473:pathology*; D005260:Female; D005727:Ganglia, Spinal / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000172:deficiency / Q000378:metabolism*; D009475:Neurons, Afferent / Q000187:drug effects* / Q000378:metabolism; D013311:Streptozocin; D013373:Substance P / Q000172:deficiency / Q000378:metabolism*
chemical_list: D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D013373:Substance P; D013311:Streptozocin; D015740:Calcitonin Gene-Related Peptide